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Abstract
The functional and molecular properties of system L in human mammary cancer cells (MDA-MB-231 and MCF-7) have been
examined. All transport experiments were conducted under Na+-free conditions. a-Aminoisobutyric acid (AIB) uptake by MDA-MB-231
and MCF-7 cells was almost abolished by BCH (2-amino-2-norbornane-carboxylic acid). AIB uptake by MDA-MB-231 cells was also
inhibited by L-alanine (83.6%), L-lysine (75.6%) but not by L-proline. Similarly, L-lysine and L-alanine, respectively, reduced AIB influx
into MCF-7 cells by 45.3% and 63.7%. The Km of AIB uptake into MDA-MB-231 and MCF-7 cells was, respectively, 1.6 and 8.8 mM,
whereas the Vmax was, respectively, 9.7 and 110.0 nmol/mg protein/10 min. AIB efflux from MDA-MB-231 and MCF-7 cells was trans-
stimulated by BCH, L-glutamine, L-alanine, L-leucine, L-lysine and AIB (all at 2 mM). In contrast, L-glutamate, L-proline, L-arginine and
MeAIB had no effect. The interaction between L-lysine and AIB efflux was one of low affinity. The fractional release of AIB from MDA-
MB-231 cells was trans-accelerated by D-leucine and D-tryptophan but not by D-alanine. MDA-MB-231 and MCF-7 cells expressed LAT1
and CD98 mRNA. MCF-7 cells also expressed LAT2 mRNA. The results suggest that AIB transport in mammary cancer cells under Na+-
free conditions is predominantly via system L which acts as an exchange mechanism. The differences in the kinetics of AIB transport
between MDA-MB-231 and MCF-7 cells may be due to the differential expression of LAT2.
D 2003 Elsevier Science B.V. All rights reserved.
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1. Introduction
System L is a Na+-independent, BCH-sensitive amino
acid transport system which accepts neutral amino acids as
substrates. It became apparent from functional studies that
system L was not a single transporter and recent molecular
studies have shown that there are at least two isoforms [1–3].
Two proteins, termed LAT1 and LAT2, induce system L-like
activity when co-expressed with CD98 (formerly referred to
as 4F2hc) [4–9]. Thus, the L system carrier protein is a
heterodimer consisting of a light chain (LAT1 or LAT2) and
a heavy chain (CD98), which are joined by a disulfide bond.
LAT1 and LAT2 differ from one another with respect to their
tissue distribution, kinetics, substrate specificity and pH
dependence [3]. LAT1 preferentially transports large neutral
amino acids such as L-phenylalanine, L-tryptophan, L-leucine
and L-tyrosine with high affinity and also transports certain
amino acid D-isomers. The substrate specificity of LAT2
appears to be somewhat wider than LAT1 but the amino
acids are transported with lower affinity. Indeed, a major
distinguishing feature between LAT1 and LAT2 is that the
latter transports L-alanine at physiological concentrations
[8,9]. It appears that LAT1 acts as an exchange mechanism,
thus, amino acid transport via LAT1 is readily stimulated by
trans-amino acids [4,10]. There appears to be some con-
troversy as to whether or not LAT2 acts as an exchange
system. On the one hand Pineda et al. [6], Rossier et al. [9]
and Meier et al. [10] have shown that amino acid efflux via
LAT2 depends upon the presence of extracellular substrate.
In contrast, Segawa et al. [7] reported that LAT2 could
operate as a uniporter.
It has long been recognised that the transport of amino
acids via system L is important for cellular nutrition [11].
However, it is becoming apparent that system L can also
transport amino acid related compounds [12,13]. For exam-
ple, several groups have reported that LAT1 is able to
transport iodothyronine [14–16]. In addition, system L
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may participate in metal ion homeostasis given that LAT1
and LAT2 transports methylmercury complexed to L-cys-
teine [17].
It has also been shown that LAT1/CD98 is related to
tumour growth which has given rise to the suggestion that
LAT1 may be a useful therapeutic target [18,19]. In relation
to this, it has been reported that a variety of human tumour
cell lines express LAT1 [20]. In spite of the potentially
interesting relationship between system L (LAT1) and
tumour size, very little is known about the properties of
amino acid transport in human mammary cancer cells. In
view of this, we have examined the functional and molec-
ular characteristics of system L in two human breast cancer
cell lines, namely MDA-MB-231 and MCF-7 which are,
respectively estrogen receptor-negative and -positive cells.
The results show that both cell lines exhibit system L
activity. However, the functional characteristics of system
L in the two cell lines appear to be different from that
reported elsewhere and the molecular distribution of LAT1
and LAT2 differs between MCF-7 and MDA-MB-231 cells.
2. Methods
2.1. Culture of MDA-MB-231 and MCF-7 cells
MDA-MB-231 and MCF-7 cells were cultured in Dul-
becco’s Modified Eagle Medium (DMEM) supplemented
with L-glutamine (2 mM), heat-inactivated fetal bovine
serum, (10%), penicillin (50 IU/ml) and streptomycin (50
Ag/ml). Cells were cultured at 37 jC in a gas phase of air
with 5% CO2. Cells were seeded in 35 mm culture wells
containing 2 ml of culture medium at a density of 0.3–
1.0 106 cells per well. The cells were cultured for 1–3
days and were used at 60–90% confluency.
2.2. Amino acid uptake by MDA-MB-231 and MCF-7 cells
The unidirectional influx of a-aminoisobutyric acid
(AIB) into MDA-MB-231 and MCF-7 cells was assayed
using [3H]AIB (ICN Biomedicals, specific activity 10 Ci/
mmol) as tracer. The culture medium was removed and the
cells were washed ( 3) with 3 ml of a buffer containing
(mM) 0.01 AIB, 135 choline-Cl, 5 KCl, 2 CaCl2, 1 MgSO4,
10 glucose and 10 Tris–MOPS, pH 7.4. Following this, the
cells were preincubated for 5 min at 37 jC in 3 ml of an
appropriate buffer (see figure legends for precise details).
AIB uptake experiments were initiated by aspirating the
preincubation buffer and replacing it with 1 ml of a buffer
containing (mM) 0.01 AIB, 135 choline-Cl, 5 KCl, 2 CaCl2,
1 MgSO4, 10 glucose and 10 Tris–MOPS, pH 7.4 plus 3
ACi of [3H]AIB and 0.4 ACi [14C] sucrose (Amersham PLC,
specific activity 615 mCi/mmol), together with other addi-
tions such as unlabelled amino acids. Radiolabelled sucrose
was used to correct for [3H]AIB associated with the extrac-
ellular compartment (i.e. to correct for incomplete washing
of the cells). The specific activity of the isotopes in the
incubation buffer was determined by counting the radio-
activity associated with 10 Al of buffer. These samples were
prepared for counting by adding 0.5 ml of distilled H2O and
10 ml of UltimaGold liquid scintillation fluid. At a prede-
termined time, the incubation buffer was aspirated and the
cells were washed four times with 3 ml of an ice-cold
solution containing (mM) 135 choline-Cl, 5 KCl, 2 KCl, 1
MgSO4, 10 glucose and 10 Tris–MOPS, pH 7.4. Following
this, the cells were incubated in 1 ml of distilled H2O for at
least 3 h during which time the lysate was frequently
agitated. A sample of the lysate (0.5 ml) was prepared for
counting by adding 10 ml of UltimaGold liquid scintillation
cocktail. Samples of the lysate (0.1 ml) were taken to
determine the protein content using the Lowry assay. AIB
uptake by the cells was calculated according to Eq. (1):
½AIBc ¼ ð½AIBt  ðF½AIBmÞÞ=P ð1Þ
where [AIB]c is the amount of AIB in the cells (pmol/mg
protein), [AIB]t is the total amount of AIB in the lysate
(pmol), [AIB]m is the amount of AIB in the incubation
medium (pmol), F is the ratio of radiolabelled sucrose in the
lysate to that in the incubation medium and P is the amount
of protein in the lysate (mg).
2.3. Amino acid efflux from MDA-MB-231 and MCF-7 cells
The efflux of AIB from MDA-MB-231 and MCF-7 cells
was assayed using [3H]AIB as tracer. After removing the
culture medium, the cells were washed ( 3) with 2 ml of a
buffer containing (mM) 135 choline-Cl, 5 KCl, 2 CaCl2, 1
MgSO4, 10 glucose and 10 Tris–MOPS, pH 7.4. The cells
were loaded with radiolabelled AIB over a period of 60 min
at 37 jC by incubating in 2 ml of a buffer similar in
composition to that just described except that it also con-
tained 1–2 ACi/ml of [3H]AIB. After the loading period, the
cells were washed four times in rapid succession with a
radioactive-free buffer similar in composition to that
described above. The efflux of radiolabelled AIB from the
cells was measured by the sequential addition and removal
of 2 ml of buffer (see figure legends for details of compo-
sition) at 1-min intervals. The first sample was discarded
because it contained a significant amount of isotope derived
from the extracellular compartment. At the end of the wash-
out period, cells were incubated in 2 ml of distilled water for
at least 3 h to determine the amount of radioactivity
remaining in the cells. Samples were prepared for counting
by adding 10 ml of UltimaGold liquid scintillation cocktail.
The fractional release for each collection period was calcu-
lated according to Eq. (2):
Fractional release ðmin1Þ ¼ dX=ðdtXtÞ ð2Þ
where dX is the amount of radiolabelled AIB released from
the cells in the time interval dt and Xt is the amount of
isotope in the cells at the start of the sampling period.
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2.4. RNA isolation and RT-PCR
Total cellular RNA was isolated from human placental
tissue (following removal of the maternal decidua and
chorionic plate) and cultured mammary cells using guani-
dinium thiocyanate and caesium chloride centrifugation
[21]. RNA was resuspended in water and the concentration
determined by the A260, where one A260 corresponds to 40
Ag of RNA. The integrity of the RNA was checked by
electrophoresis in a 1.2% agarose gel containing 2.2 M
formaldehyde and 0.5 Ag/ml of ethidium bromide [22].
PCR primers for LAT1, LAT2 and CD98 were designed
from the sequences available in GenBank (accession num-
bers: LAT1, AF104032; LAT2, AF171669; CD98 (4F2hc),
AH001404). Primer pairs were designed to different exons to
prevent the amplification of any contaminating DNA. The




GAA 3V; LAT2, forward 5VAGCCTGATATCCCCCGCCC-





Fig. 1. The effect of external amino acids on AIB uptake by (a) MDA-MB-231 and (b) MCF-7 cells. Cells were incubated in a medium containing (mM) 0.01
AIB, 135 choline-Cl, 5 KCl, 2 CaCl2, 1 MgSO4, 10 glucose and 10 Tris–MOPS, pH 7.4 plus 3 ACi [3H]AIB, 0.4 ACi [14C]sucroseF amino acids (10 mM)
as required. Uptake was assayed at 37 jC after 10 min of incubation. The numbers in parentheses represent the number of experiments performed with each
amino acid. Insets show the time course of AIB uptake into MDA-MB-231 and MCF-7 cells (n= 3; F S.E.). The incubation medium was the same as that
described above.
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CAGA 3V. The expected sizes of the PCR products were 420
bp for LAT1, 442 bp for LAT2 and 224 bp for CD98.
cDNA was prepared from 1-Ag samples of total RNA
using M-MLV reverse transcriptase (Promega) and random
hexamers (Pharmacia). The cDNA (0.05 Ag equivalent to
RNA) was PCR amplified using Taq polymerase (Thermo-
Start Master Mix, ABgene) and 2 AM of each of the
appropriate primer pair, in a total volume of 25 Al. Samples
were initially denatured at 94 jC for 5 min, followed by 35
cycles of 92 jC for 30 s, 59.8 jC (for LAT1 and LAT2) or
60.3 jC (for CD98) for 30 s, and 72 jC for 30 s, with a final
5 min extension at 72 jC. Aliquots (5 Al) of the PCRs were
then resolved on a 1% agarose/TBE gel and the products
visualised by ethidium bromide staining. Confirmation that
the RT-PCR products were those expected was done either
by sequencing the products (LAT1 and LAT2) or by
restriction digest analysis (CD98).
3. Statistics
Differences were assessed using Student’s paired or
unpaired t-test as appropriate and were considered signifi-
cant when P < 0.05.
4. Results
4.1. AIB uptake by MDA-MB-231 and MCF-7 cells
Preliminary experiments established that the uptake of
AIB by both MDA-MB-231 and MCF-7 cells was linear
for at least 15 min under Na+-free conditions (Fig. 1a and
b, insets). The rate of AIB uptake (10 AM) by MDA-MB-
231 and MCF-7 cells was, respectively, 6.88F 0.89 and
19.11F 3.09 nmol/mg protein/min (F S.E., n = 3). The
next step in the investigation was to test the effect of a
variety of amino acids, added to the incubation medium,
on AIB uptake by the cultured cells. In this set of experi-
ments, the effect of each extracellular amino acid (10 mM)
on AIB influx was assayed after 10 min of incubation. Fig.
1a shows that AIB uptake by MDA-MB-231 cells was
markedly reduced by the system L inhibitor BCH (96.2F
1.9%; P < 0.001). Indeed, it appears that the BCH-sensitive
pathway, and thus system L, is the major, if not only,
pathway for AIB uptake by MDA-MB-231 cells under
Na+-free conditions. AIB uptake by MDA-MB-231 cells
Fig. 2. Dose– response curve of BCH inhibition of AIB uptake by MDA-
MB-231 cells. The incubation medium contained (mM) 0.001–10 BCH,
0.01 AIB, 135 choline-Cl, 5 KCl, 2 CaCl2, 1 MgSO4, 10 glucose, 10 Tris–
MOPS, pH 7.4 plus 3 ACi [3H]AIB and 0.4 ACi [14C]sucrose. Uptake was
assayed at 37 jC after 10 min of incubation. The results are meanF S.E.;
n= 5.
Fig. 3. The kinetics of AIB uptake by (a) MDA-MB-231 and (b) MCF-7
cells. The incubation medium contained (mM) 0.01–10 AIB, 135 choline-
Cl, 5 KCl, 2 CaCl2, 1 MgSO4, 10 glucose and 10 Tris–MOPS, pH 7.4 plus
3 ACi [3H]AIB and 0.4 ACi [14C]sucrose. Uptake was assayed at 37 jC after
10 min of incubation. Each point is the meanF S.E. of four experiments.
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was also inhibited by L-alanine (83.6F 3.9%; P < 0.01) but
not by L-proline. It is evident that the BCH-sensitive
pathway for AIB uptake also accepts L-lysine as a substrate
given that L-lysine inhibited AIB uptake by 75.6F 5.9%
(P < 0.002). Fig. 1b shows that the uptake of AIB by
MCF-7 cells was also markedly inhibited by BCH
(95.1F1.0%; P < 0.01). Again, it appears that the BCH-
sensitive route, and thus system L, may be the only
available pathway for AIB uptake by MCF-7 cells under
Na+-free conditions. The BCH-sensitive pathway for AIB
uptake into MCF-7 cells was also inhibited by L-alanine
(63.7F 2.8%; P < 0.001) and L-lysine (45.3F 6.9%;
P < 0.05) but not by L-proline (Fig. 1b). Fig. 2 shows that
BCH inhibited AIB uptake by MDA-MB-231 cells in a
concentration-dependent manner. The IC50 was approxi-
mately 50 AM.
AIB uptake by MDA-MB-231 and MCF-7 cells followed
Michaelis–Menton kinetics (Fig. 3a and b). We are aware,
however, that the kinetic data could be described by more
complex models. The kinetic constants were lower in MDA-
MB-231 cells compared with the values obtained with
MCF-7 cells. The Km of AIB uptake into MDA-MB-231
and MCF-7 cells was, respectively, 1.64F 0.36 and
8.81F 2.16 mM (n = 4; F S.E.; P < 0.02). The Vmax of
AIB influx into MDA-MB-231 and MCF-7 cells was,
Fig. 4. The effect of external BCH on AIB efflux from (a) MDA-MB-231
and (b) MCF-7 cells. The incubation medium contained (mM) 135 choline-
Cl, 5 KCl, 2 CaCl2, 1 MgSO4, 10 glucose and 10 Tris–MOPS, pH 7.4.
When AIB efflux from MDA-MB-231 cells was examined, BCH was
added to the incubation medium at a concentration of 1 AM (D), 10 AM
(o), 50 AM (5), 75 AM (E), 100 AM (.) and 2 mM (n). Each point is the
meanF S.E. of four experiments. When AIB efflux from MCF-7 cells was
studied, BCH was added to the incubation medium at a concentration of 10
AM (.), 50 AM (E), 100 AM (z) and 2 mM (n). Each point is the
meanF S.E. of four experiments.
Fig. 5. (a) The effect of 2 mM L-lysine (.), 0.1 mM L-lysine (n) and 2 mM
L-arginine (E) on AIB efflux from MDA-MB-231. The incubation medium
contained (mM) 135 choline-Cl, 5 KCl, 2 CaCl2, 1 MgSO4, 10 glucose and
10 Tris–MOPS, pH 7.4. Each point is the meanF S.E. of ten, five and four
experiments when the effects of 2 mM L-lysine, 0.1 mM L-lysine, and 2mM
L-arginine were examined, respectively. (b) The effect of 2 mM L-lysine (.)
and L-arginine (E) on AIB efflux from MCF-7 cells. The incubation
medium was the same as that described above. Each point is the
meanF S.E. of four and three experiments, respectively, when L-lysine
and L-arginine was used.
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respectively, 9.79F 1.40 and 110.02F 21.72 nmol/mg pro-
tein (n = 4; F S.E.; P < 0.01).
4.2. AIB efflux from MDA-MB-231 and MCF-7 cells
4.2.1. BCH trans-stimulates AIB efflux
There is good evidence that system L acts as an amino
acid exchange mechanism (e.g. see Ref. [10]). To test
whether or not system L in mammary tumour cells is an
exchange mechanism, we examined the effect of extracel-
lular BCH on the efflux of AIB from MDA-MB-231 and
MCF-7 cells. In this set of experiments, AIB efflux was first
measured from cells incubated in amino acid-free buffers
followed by buffers supplemented with varying concentra-
tions of BCH (Fig. 4a and b). It is apparent that BCH trans-
stimulated AIB efflux from both cell lines in a dose-depend-
ent fashion. Thus, BCH at a concentration of 10, 50, 75, 100
and 2000 AM, respectively, increased AIB efflux (basal-to-
peak) from MDA-MB-231 cells by 70.3% (P < 0.05),
204.4% (P < 0.02), 216.5% (P < 0.01), 244.6% (P < 0.001)
and 312.2% (P < 0.01). Note from Fig. 3a that BCH at a
concentration of 1 AM did not have any effect on AIB efflux
fromMDA-MB-231 cells. BCH at a concentration of 50, 100
and 2000 AM increased the fractional release of AIB (basal-
to-peak) from MCF-7 cells by 83.4% (P < 0.01), 98.4%
(P < 0.001) and 230.3% (P < 0.001), respectively. In con-
trast, 10 AM BCH did not significantly trans-stimulate AIB
release from MCF-7 cells.
4.2.2. The effect of cationic amino acids on AIB efflux
The finding that L-lysine inhibited the BCH-sensitive
component of AIB uptake by MDA-MB-231 and MCF-7
cells prompted us to investigate the effects of cationic
amino acids on AIB release. L-lysine, but not L-arginine,
trans-accelerated AIB efflux from MDA-MB-231 cells
when tested at a concentration of 2 mM (Fig. 5a). The
fractional release of AIB was increased (basal-to-peak)
from 0.0119F 0.0006 to 0.0358F 0.0027 (F S.E., n = 10,
P < 0.001) by the addition of L-lysine. However, the inter-
action between L-lysine and AIB efflux appears to be one of
relatively low affinity as 0.1 mM L-lysine had no effect on
AIB efflux from MDA-MB-231 cells (Fig. 5a). L-lysine (2
mM) also trans-stimulated AIB release from MCF-7 cells
(Fig. 5b). Thus, the fractional efflux of AIB was increased
(basal-to-peak) from 0.0138F 0.0014 to 0.0349F 0.0027
(F S.E., n= 6, P < 0.001). In contrast, L-arginine (2 mM)
had no effect on AIB efflux from MCF-7 cells.
4.2.3. AIB efflux is selectively trans-stimulated by external
amino acids
We also examined the effect of L-alanine, L-glutamine, L-
leucine, L-tryptophan, AIB, MeAIB, L-proline and L-glu-
Fig. 7. The effect of external L-tryptophan at 10 AM (E), 200 AM (.) and 2
mM (n) on AIB efflux from MDA-MB-231 cells. The incubation medium
contained (mM) 135 choline-Cl, 5 KCl, 2 CaCl2, 1 MgSO4, 10 glucose and
10 Tris–MOPS, pH 7.4F L-tryptophan (as indicated). Each point is the
meanF S.E. of between four and six experiments.
Fig. 6. The effect of external L-glutamine (n), L-alanine (.), L-leucine (o),
L-proline (E), L-glutamate (5), AIB (z) and MeAIB (5) on the efflux of
AIB from (a) MDA-MB-231 and (b) MCF-7 cells. The incubation medium
contained (mM) 135 choline-Cl, 5 KCl, 2 CaCl2, 1 MgSO4, 10 glucose and
10 Tris–MOPS, pH 7.4. External amino acids were added to the incubation
medium to give a final concentration of 2 mM. Each point represents the
meanF S.E. of between three and six observations.
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tamine (all tested at 2 mM) on AIB efflux from MDA-MB-
231 cells. It is apparent from Fig. 6a that L-alanine
(P < 0.001), L-glutamine (P < 0.01), L-leucine (P < 0.001)
and AIB ( P < 0.02) all trans-stimulated AIB efflux,
whereas no effect was found with L-proline, L-glutamate
and MeAIB. L-alanine at a concentration of 0.1 mM had no
significant effect on AIB release from MDA-MB-231 cells
(results not shown). Extracellular L-tryptophan stimulated
AIB efflux from MDA-MB-231 cells in a dose-dependent
manner (Fig. 7). Thus, L-tryptophan at a concentration of
10, 200 and 2000 AM, respectively stimulated AIB release
(basal-to-peak) from MDA-MB-231 cells by 63.5%
(P < 0.05), 181.9% (P < 0.001) and 219.5% (P < 0.001).
The effect of external amino acids (2 mM) on AIB efflux
from MCF-7 cells was also examined (Fig. 6b). L-alanine
(P < 0.001), L-glutamine (P < 0.001), L-leucine (P < 0.001)
and AIB (P < 0.01) trans-stimulated AIB efflux from
MCF-7 cells. On the other hand L-pro, L-glu and MeAIB
had no effect.
4.2.4. The effect of D-isomers on AIB efflux
Fig. 8 illustrates the effect of amino acid D-isomers on
AIB efflux from MDA-MB-231 cells. For comparison, the
effects of their L-isomer counterparts are also shown. It is
evident that D-tryptophan ( P < 0.002) and D-leucine
(P < 0.001) effectively trans-accelerated AIB efflux. Indeed,
at a concentration of 2 mM, it appears that D-tryptophan and
D-leucine are more effective than their L-isomer counterparts.
In contrast, D-alanine did not trans-stimulate AIB efflux from
MDA-MB-231 cells. D-leucine (2 mM) also stimulated AIB
release from MCF-7 cells: the effect was greater than that
found with L-leucine (results not shown).
Fig. 8. The effect of external D-leucine (a), D-tryptophan (b) and D-alanine
(c) on AIB efflux from MDA-MB-231 cells. Shown for comparison are the
effects of their L-isomer counterparts. The data relating to the effects of the
D-isomers are represented by the filled circles. The incubation medium
contained (mM) 135 choline-Cl, 5 KCl, 2 CaCl2, 1 MgSO4, 10 glucose and
10 Tris–MOPS, pH 7.4. When required, the amino acids were used at a
concentration of 2 mM. Each point is the meanF S.E. of four experiments.
The data relating to the effect of the L-isomers is the same as that shown in
Figs. 6a and 7.
Fig. 9. The effect of external L-lysine in the presence of external BCH on
AIB efflux from MDA-MB-231 (.) and MCF-7 cells (o). Efflux was
measured into a medium containing (mM) 135 choline-Cl, 5 KCl, 2 CaCl2,
1 MgSO4, 10 glucose, 10 Tris–MOPS, pH 7.4 and 2 BCH. External
L-lysine was used at a concentration of 2 mM. Each point represents the
meanF S.E. of three and four observations, respectively, when MDA-MB-
231 and MCF-7 cells were used.
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4.2.5. BCH, L-lysine and D-leucine share a pathway for
transport
It is clear that both BCH and L-lysine stimulate AIB efflux
from MDA-MB-231 and MCF-7 cells. However, BCH and
L-lysine could either stimulate AIB efflux via a common or
separate pathways. To distinguish between the two possibil-
ities we examined the effect of L-lysine in the presence of
BCH. Thus, we measured AIB efflux from cells incubated
first in a medium containing BCH followed by one contain-
ing both BCH and L-lysine. The results of these experiments
are shown in Fig. 9. It is clear that L-lysine loses the capacity
to trans-stimulate AIB efflux from MDA-MB-231 and
MCF-7 cells in the presence of BCH which is consistent
with the notion that both amino acids share a pathway(s) for
transport. In addition, it is apparent that D-leucine and BCH
share a pathway for transport in MDA-MB-231 cells given
that the efficacy of D-leucine to trans-stimulate AIB efflux
was markedly diminished in the presence of BCH (results
not shown).
4.2.6. Molecular identity of system L in MDA-MB-231 and
MCF-7 cells
We subjected total RNA isolated from MDA-MB-231
and MCF-7 cells to RT-PCR to test for the presence of
LAT1, LAT2 and CD98 (Fig. 10). Human placental tissue
was used as a positive control since it has been reported that
placental trophoblast expresses all three transcripts [23].
Products for the expected size for LAT1, LAT2 and CD98
were amplified from MCF-7 cells. In contrast, only LAT1
and CD98 mRNA was found in MDA-MB-231 cells.
5. Discussion
5.1. Evidence for system L activity in MDA-MB-231 and
MCF-7 cells
The present study was undertaken to characterise the
functional and molecular properties of system L in cultured
human breast cancer cell lines namely, MDA-MB-231 and
MCF-7 cells. Given that we wanted to study amino acid
efflux as well as influx, we used AIB as a substrate and thus
the confounding issue of intracellular metabolism was
avoided. The use of AIB is valid given that this non-
metabolizable amino acid analogue interacts with system L
in a variety of cell types [24–26]. In the present study,
system L activity was defined as BCH-sensitive AIB trans-
port measured under Na+-free conditions. BCH is regarded
as a relatively specific substrate of system L. Based on these
criteria, the results clearly show that AIB uptake into both
cell lines is via system L. Indeed, under our experimental
conditions, system L appears to be the major, if not the sole,
pathway for AIB uptake into MDA-MB-231 and MCF-7
cells.
The results show that BCH, when added to the incuba-
tion medium, stimulated the efflux of AIB from MDA-MB-
231 and MCF-7 cells. This suggests that system L in these
mammary cancer cell lines acts as an exchange mechanism.
This is in agreement with the findings that both LAT1 and
LAT2, when co-expressed with CD98, act as amino acid
exchangers and not uniporters [10]. Moreover, the stimula-
tion of AIB efflux from the mammary cell lines by
extracellular BCH suggests that BCH is actually transported
by system L and is not simply acting as a cis-inhibitor of
amino acid uptake. Other amino acids including L-gluta-
mine, L-leucine, L-alanine, and AIB acted to trans-acceler-
ate AIB efflux from MDA-MB-231 and MCF-7 cells. Thus,
it appears that system L has a relatively wide substrate
specificity in these cell lines. The effect of extracellular
amino acids was, however, specific since MeAIB, L-gluta-
mate and L-proline had no effect on AIB release.
Although it is apparent that system L in MDA-MB-231
and MCF-7 cells can operate as an exchanger, the question
which arises is: does system L have to act as an obligatory
amino acid exchanger? In this connection, it is interesting to
note that there was a significant efflux of AIB from both cell
types even in the absence of extracellular amino acids. If
this flux is mediated via system L, then it would appear that
the transporter is able to operate as a uniporter. However, at
present, we cannot rule out the possibility that AIB efflux
under zero-trans conditions is via a pathway(s) other than
the L system.
5.2. System L in mammary cancer cell lines interacts with
L-lysine
One interesting feature about the present study is the
finding that L-lysine interacts with AIB transport in MDA-
Fig. 10. LAT1, LAT2 and CD98 RT-PCR products from human placenta,
MCF-7, MDA-MB-231 cells. The control track represents PCR in the
absence of cDNA.
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MB-231 and MCF-7 cells. Thus, AIB influx and efflux was
respectively inhibited and stimulated by extracellular L-
lysine, suggesting that system L in MDA-MB-231 and
MCF-7 cells accepts L-lysine as a substrate. At first sight,
the interaction between AIB transport and L-lysine could be
taken as evidence for transport via system y+L. However, this
can be ruled out on the basis that system y+L is not inhibited
by BCH even at a concentration of 5 mM [27]. We are
confident that L-lysine is transported by system L in the
mammary cell lines because of the following reasons. First,
AIB uptake is almost exclusively via a BCH-sensitive path-
way. Therefore, the finding that L-lysine inhibited AIB
uptake suggests that BCH and L-lysine are acting at a
common locus. Secondly, the effect of L-lysine on AIB
efflux cannot be attributed to a stimulation of AIB efflux
via a membrane potential-sensitive pathway because L-argi-
nine had no effect. Thirdly, extracellular L-lysine did not
stimulate AIB efflux from MDA-MB-231 cells in the pres-
ence of BCH, suggesting that both amino acids are acting at a
common site. However, we must stress that the interaction
between L-lysine and system L appears to be one of relatively
low affinity. In this connection, it is striking that the onset of
trans-stimulation of AIB efflux by L-lysine is much slower
than that elicited by BCH: this may relate to the finding that
L-lysine interacts with system L with low affinity. However,
the sequential interaction between two transport systems
cannot at this stage be completely ruled out.
5.3. Molecular identity of system L in MDA-MB-231 and
MCF-7 cells
As mentioned above, LAT1 and LAT2 when co-expressed
with CD98 exhibit system L-like activity. It is apparent that
MCF-7 cells express both LAT1 and LAT2, whereas MDA-
MB-231 cells only express LAT1. How does the functional
data compare with what is known about the properties of
LAT1 and LAT2? Let us consider the data relating to the
MDA-MB-231 cells first because this appears to be the
simplest case as they only express one molecular form of
system L. LAT1 when co-expressed with CD98 in Xenopus
oocytes stimulates the transport of aromatic and large neutral
amino acids such as L-leucine, L-phenylalanine, L-tryptophan
and BCH in a Na+-independent fashion. In addition, LAT1
transports D-isomers of certain amino acids [4]. Thus, LAT1
could account for the functional properties of AIB transport
in MDA-MB-231 cells. However, the finding that AIB influx
and efflux was respectively inhibited and stimulated by
extracellular L-alanine appears at first sight to be somewhat
puzzling. One of the major distinguishing features between
LAT1 and LAT2 is that only the latter accepts L-alanine as a
substrate at physiological concentrations (e.g. see Ref. [8]).
In this connection, it must be borne in mind that the
interaction between L-alanine and AIB efflux from MDA-
MB-231 cells was one of relatively low affinity. Another
difference between the functional properties of system L in
MDA-MB-231 cells and those of LAT1 is that the former
does not appear to transport D-tryptophan. Kanai et al. [4]
have shown that LAT1 displays marked stereospecificity to
tryptophan, whereas the present results indicate that both
L and D-tryptophan are transported via system L in MDA-
MB-231 cells. The functional properties of AIB transport
in MDA-MB-231 cells and those of LAT1 appear to differ
with respect to the interaction with L-lysine. LAT1 does
not transport L-lysine when expressed in Xenopus oocytes,
whereas our results show that the BCH-sensitive pathway
does interact with L-lysine, albeit with low affinity, in a
manner which suggests that L-lysine can be considered a
substrate.
The relationship between the functional and molecular
data in MCF-7 cells is harder to interpret given that both
LAT1 and LAT2 are expressed. This is a situation similar to
that found in the lactating rat mammary gland [28]. How-
ever, the finding that D-leucine was effective at stimulating
AIB efflux suggests that LAT1 plays a role in AIB transport.
It is notable that the Km of AIB uptake into MCF-7 cells was
higher than the value calculated for MDA-MB-231 cells.
The higher Km may reflect transport of AIB via LAT2 given
that LAT2 has a lower affinity than LAT1 for some neutral
amino acids (e.g. see Ref. [8]).
Taken together, the results are consistent with the notion
that system L may play an important role in providing
mammary cancer cells with amino acids. The results also
suggest that LAT1 is the molecular correlate of system L in
MDA-MB-231 cells. On the other hand, system L activity in
MCF-7 cells may be attributed to both LAT1 and LAT2. The
observation that MCF-7 cells express LAT1 and LAT2,
whereas MDA-MB-231 cells express only LAT1 may be
of some clinical significance. If the expression of the amino
acid transporters differs between estrogen receptor-positive
and -negative tumours in a similar fashion, then the pattern
of LAT1/LAT2 expression could be used as an additional
diagnostic tool.
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